Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent

Our first generation of hydroxyethylamine transition-state mimetic BACE-1 inhibitors allowed us to validate BACE-1 as a key target for Alzheimer’s disease by demonstrating amyloid lowering in an animal model, albeit at rather high doses. Finding a molecule from this series which was active at lower oral doses proved elusive and demonstrated the need to find a novel series of inhibitors with improved pharmacokinetics. This Letter describes the discovery of such inhibitors.

This article discloses the strategy that led to the discovery of a second series of hydroxyethylamine BACE-1 inhibitors with non-prime side substituents of higher binding efficiency.Figure optionsDownload as PowerPoint slide